Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W. Joseph(Daiichi Sankyo (United States)), Tara C. Gangadhar(University of Pennsylvania), Andrea Perrone(Università Cattolica del Sacro Cuore), Roxana Dronca(Dana-Farber Cancer Institute), Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Cedars-Sinai Medical Center), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sunyu Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Dinesh P. de Alwis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keaven M. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Jin Zhang(Shanghai Jiao Tong University), Caroline Robert(Institut Gustave Roussy), Richard Kefford(Broad Institute), Adil Daud(University of California, San Francisco)
Cited by 38
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k